Live Salesforce, Inc. Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow Bicara Therapeutics Inc.

Get SEC filing alerts via email and in your feed for Bicara Therapeutics Inc.

BCAX

Bicara Therapeutics Inc.

About Bicara Therapeutics Inc.

Bicara Therapeutics is a clinical-stage biopharmaceutical company developing bifunctional antibody therapies targeting solid tumors. Its lead product, ficerafusp alfa, combines EGFR inhibition with TGF-β blockade to enhance anti-tumor activity, overcome resistance, and improve tolerability. Focused on cancers like head and neck squamous cell carcinoma, the company aims to deliver targeted, durable treatments that modulate the tumor microenvironment and activate immune responses.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from Bicara Therapeutics Inc.

1
1
Bicara Therapeutics Inc. Bicara Therapeutics Reports $56.2 Million Net Loss in Q1 2026 Amid Increased R&D Expenses

Via official filing (AI summary) | 24 days ago | 0 comments

2
1
Bicara Therapeutics Inc. Bicara Therapeutics Reports $138M Net Loss and Business Updates in Annual Filing

Via official filing (AI summary) | 2 months ago | 0 comments

3
1
Bicara Therapeutics Inc. Bicara Therapeutics Reports $36.3 Million Net Loss in Latest Quarter, Increases R&D Spending

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
Bicara Therapeutics Inc. Bicara Therapeutics Reports $27.4 Million Net Loss in Q2 2025 Amid Increased R&D Expenses

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
Bicara Therapeutics Inc. Bicara Therapeutics Reports $36.8 Million Net Loss and Increased R&D Expenses in Latest Quarter

Via official filing (AI summary) | about 1 year ago | 0 comments